Drug
Iov 3001
Iov 3001: highest development phase Phase 1/2, developed by Iovance Biotherapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Iovance Biotherapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| IOV-3001 NCT06940739 | Phase 1/2 | Unresectable Melanoma |
Latest
No recent events.
Follow Iov 3001 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.